Rheumatoid Arthritis Market is expected to increase from $56.6 billio Rheumatoid Arthritis Market 2020 | Page 5

3.1 Overview 21
3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 21
3.2.1 Methotrexate-Based Products 21
3.2.2 Xeljanz (tofacitinib) – Pfizer 22
3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 23
3.3.1 Remicade (infliximab) – Johnson and Johnson, Merck 23
3.3.2 Remsima – infliximab biosimilar 24
3.3.3 Humira (adalimumab) – Abbvie 24
3.3.4 Enbrel (etanercept) – Amgen, Pfizer and Takeda Pharmaceutical 26
3.3.5 Rituxan (rituximab) – Genentech (Roche), Biogen IDEC 27
3.3.6 Reditux (Non-comparable Biologic of Rituxan) 28
3.3.7 AcellBia (rituximab biosimilar) 28
Read Complete Report with TOC @ http://www.radiantinsights.com/research/rheumatoidarthritis-market-to-2020-a-crowded-market-characterized-by-modest-growth
3.3.8 Orencia (abatacept) – Bristol-Myers Squibb 29
3.3.9 Simponi (golimumab) – Johnson and Johnson, Merck 30
3.3.10 Cimzia (certolizumab pegol) – UCB 31
3.3.11 Kineret (anakinra) – Swedish Orphan Biovitrum 32
3.3.12 Actemra (tocilizumab) – Roche 33
3.3.13 Comparative Safety and Efficacy 34
3.4 Unmet Need 37

4 Pipeline Landscape 38
4.1 Overview 38
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
38